Franklin Resources Inc Kal Vista Pharmaceuticals, Inc. Transaction History

Franklin Resources Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$8.16 - $15.1 $10.1 Million - $18.7 Million	-1,239,731 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$11.2 - $16.97 $139,003 - $210,614	-12,411 Reduced 0.99%	1,239,731 $18.3 Million
Q4 2021 Feb 11, 2022	SELL	$12.36 - $18.28 $1.83 Million - $2.71 Million	-148,317 Reduced 10.59%	1,252,142 $16.6 Million
Q3 2021 Nov 12, 2021	SELL	$17.11 - $24.49 $946,764 - $1.36 Million	-55,334 Reduced 3.8%	1,400,459 $24.4 Million
Q2 2021 Aug 13, 2021	BUY	$23.12 - $29.91 $3.89 Million - $5.03 Million	168,132 Added 13.06%	1,455,793 $34.9 Million
Q1 2021 May 13, 2021	BUY	$14.69 - $42.57 $13 Million - $37.8 Million	887,951 Added 222.15%	1,287,661 $33.1 Million
Q4 2020 Feb 10, 2021	BUY	$12.88 - $19.47 $2.14 Million - $3.23 Million	165,810 Added 70.89%	399,710 $7.59 Million
Q1 2020 May 13, 2020	SELL	$5.8 - $18.56 $287,680 - $920,575	-49,600 Reduced 17.5%	233,900 $1.79 Million
Q4 2019 Feb 12, 2020	BUY	$10.31 - $17.81 $2.92 Million - $5.05 Million	283,500 New	283,500 $5.05 Million

125

47.8M

551K

110K

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $193M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

Stay updated on Franklin Resources Inc with notifications on news.